These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3250450)

  • 1. Cisplatin chemotherapy of ovarian cancer: is short-term in vitro chemosensitivity predictive of long-term patient survival?
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    Aust N Z J Obstet Gynaecol; 1988 Nov; 28(4):313-7. PubMed ID: 3250450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term in vitro chemosensitivity testing of tumours of the ovary, cervix and uterus. Measurement of DNA metabolism by 3H thymidine incorporation.
    Khoo SK; Hurst T; Webb MJ; Mackay EV
    Aust N Z J Obstet Gynaecol; 1986 Nov; 26(4):288-94. PubMed ID: 3469997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment.
    Wilson AP; Ford CH; Newman CE; Howell A
    Br J Cancer; 1987 Dec; 56(6):763-73. PubMed ID: 3435704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitivity testing of ovarian cancer: results of a rapid in vitro biochemical assay.
    Khoo SK; Hurst T; Webb MJ
    Aust N Z J Obstet Gynaecol; 1985 Aug; 25(3):215-20. PubMed ID: 3866561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of in vitro drug sensitivity testing based on short-term effects on DNA and RNA metabolism in ovarian cancer.
    Khoo SK; Hurst T; Webb MJ; Dickie G; Kearsley J; Parsons PG; Mackay EV
    J Surg Oncol; 1989 Jul; 41(3):201-5. PubMed ID: 2747246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
    Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
    Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Br J Cancer; 1996 Dec; 74(11):1730-3. PubMed ID: 8956785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
    Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
    Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
    Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
    Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro sensitivity of ovarian cancer as determined by a short-term biochemical assay: comparison between primary and metastatic sites in the same patient.
    Khoo SK; Hurst T; Lark J; Webb MJ; Parsons P; Mackay EV
    Gynecol Oncol; 1989 Feb; 32(2):151-5. PubMed ID: 2910775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitivity testing of primary cultures of Merkel cell cancer.
    Kearsley JH; Hurst T; Khoo SK
    Anticancer Drugs; 1993 Oct; 4(5):571-5. PubMed ID: 8292815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.
    Rogers PM; Beale PJ; Al-Moundhri M; Boxall F; Patterson L; Valenti M; Raynaud F; Hobbs S; Johnston S; Kelland LR
    Int J Cancer; 2002 Feb; 97(6):858-63. PubMed ID: 11857368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A newly developed in vitro chemosensitivity test (nuclear damage assay): application to ovarian cancer.
    Sekiya S; Iijima N; Oosaki T; Takamizawa H; Tokita H
    Gynecol Oncol; 1991 Feb; 40(2):138-43. PubMed ID: 2010105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.